๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Long-term remission in a patient with BCR/ABL-positive acute myeloid leukaemia on maintenance therapy with imatinib

โœ Scribed by Enrico Schalk; Silke Neum; Sandra Kranz; Katrin Scheinpflug; Martin Mohren


Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
190 KB
Volume
33
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Long-term remission in BCR/ABL-positive
โœ Franca Pompetti; Antonio Spadano; Antonella Sau; Antonio Mennucci; Rosa Russo; V ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 363 KB

BCR/ABL-positive acute myeloid leukemia (AML) is a rare disease, characterized by a poor prognosis, with resistance to induction chemotherapy and frequent relapses in responsive patients. Here we report a case of BCR/ABL-positive AML-M6 who, after relapse, was treated with Imatinib Mesylate (600 mg/

Is it possible to discontinue imatinib m
โœ Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 111 KB

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o

Long-term survival of patients with acut
โœ Clara D. Bloomfield; Cynthia Shuma; Linda Regal; Preben P. Philip; Dieter K. Hos ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 284 KB ๐Ÿ‘ 2 views

## Background: In 1982, the fourth international workshop on chromosomes in leukemia reviewed data prospectively collected on 716 patients with acute myeloid leukemia (aml) diagnosed between 1980 and 1982. the present study examined the extended follow-up on these patients. ## Methods: The analys